Aycobacterium avium strains susceptible to clarithromycin and azithromycin contain mutants resistant to these macrolides with a frequency of 1.1 x 10-10 to 1.2 x 10-6. Cross-resistance between clarithromycin and azithromycin was demonstrated with mutants selected in the laboratory as well as with resistant strains isolated from patients. The susceptibility-resistance patterns of the macrolide-resistant strains with drugs other than macrolides were the same as those of the onrginal susceptible strains. The emergence of clarithromycin resistance in patients was a result of multiplication of the preexisting resistant mutants that survived the elimination of bacteria during the initial period of treatment and was an exclusive cause of the relapse of bacteremia.
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Clarithromycin, a new macrolide, has been shown to have activity against Mycobacterium avium in various models including experiments in culture media (1, 2, 4, 7, 9, 12, 17, 22) , macrophages (16, 18, 19, 21, 24) , and mice (7, 13, 14) . The effectiveness of this drug in the elimination of M. avium bacteremia in patients with AIDS has been shown in controlled clinical trials (3, 6, 10) . Another macrolide, azithromycin, has also been shown to be effective in the therapy of M. avium infections in patients with AIDS (23, 26) . Clinical trials with both macrolides have had limited periods of observation, usually less than 12 weeks. Recent reports on prolonged monotherapy with clarithromycin or azithromycin showed that after a period of elimination of the bacteria, a relapse of bacteremia took place in many patients (3, 5, 23, 26) . Those reports also implied that prolonged monotherapy may lead to the emergence of drug resistance.
The goals of the present study were to address the following various aspects of drug resistance of M. avium to new macrolides, especially clarithromycin: (i) the frequency of clarithromycin-and azithromycin-resistant mutants in susceptible M. avium strains and the degree of resistance of these mutants, (ii) cross-resistance between clarithromycin and azithromycin, (iii) comparison of the drug susceptibilityresistance patterns between the original strains and their resistant mutants in experiments with other drugs, and (iv) drug susceptibilities of strains isolated from patients with AIDS and bacteremia at the beginning of therapy and at the time of relapse. In the present study, we analyzed the bacteriological response to clarithromycin monotherapy and presented a general description of the phenomenon of the emerging resistance of M. avium to this drug. The genetic basis of macrolide resistance in M. avium was not among the goals of the present study. Neither did we make an attempt to address such issues as the rate of mutation or mechanisms of resistance.
MATERIALS AND METHODS Antimicrobial agents. Clarithromycin was obtained from Abbott Laboratories (Abbott Park, Ill.). The drug was dissolved in dimethyl sulfoxide (DMSO; 100 mg/10 ml). This stock solution was diluted further with DMSO to make * Corresponding author. appropriate working solutions, which were kept for no more than 1 month. Azithromycin was obtained from Pfizer Central Research Division (Groton, Conn.), solutions were made according to the manufacturer's instruction in phosphate buffer at pH 6.5, and samples were stored at -70°C.
Development of drug-resistant mutants in vitro. MuellerHinton agar supplemented with oleic acid-albumin-dextrose complex (OADC) (pH 7.4) was used in petri dishes divided into quadrants. Two sets of plates were prepared: one with clarithromycin at concentrations of 4.0, 8.0, 16.0, 32.0, and 64.0 ,ug/ml and one with azithromycin at concentrations of 64.0, 128.0, 256.0, and 512.0 ,ug/ml. Four strains isolated from patients with AIDS before therapy were selected for the studies described here. Each strain was subcultivated in 7H9 broth for 5 to 7 days to an optical density greater than that of a McFarland no. 3 standard, and 0.25 ml of the bacterial suspension was placed in each of the quadrants containing the various drug concentrations. Serial 10-fold dilutions from the same bacterial suspension were simultaneously plated on whole drug-free plates to estimate the number of viable bacteria in the inoculum. After incubation for 3 weeks at 37°C, the colonies were counted, and the proportion growing in the presence of various drug concentrations was compared with the total number of viable bacteria in the inoculum; this provided the frequency of drug resistance. The inoculum in different experiments ranged from 108 to 1012 CFU/ml. The colonies that grew in the presence of the drugs were subcultivated on agar slants containing the same drug concentrations as those in the original plates. The subcultures were used for further studies.
Strains from patients treated with clarithromycin. We selected cultures isolated from 39 patients who had been treated with clarithromycin for 150 days or longer and who had an initial level of bacteremia of greater than 10 CFU/ml, which was determined in two pretreatment blood specimens. A total of 349 cultures were isolated from 492 blood specimens. Thirty-nine of them were isolated before treatment, 132 were isolated during the period of decline of bacteremia, and 178 were isolated during the relapse of bacteremia. All isolates were identified as M. avium by the AccuProbe DNA-RNA hybridization technique (San Diego, Calif.). Blood specimens were collected in sodium polyanetholesulfonate-containing Vacutainers. The specimen (10.0 ml) was poured into a 50-mi Falcon tube containing 20.0 ml of lysing solution consisting of SPS and sodium desoxycholate in final concentrations of 0.06 and 0.3%, respectively. Complete lysis of both erythrocytes and leukocytes occurred within a few minutes. The tubes were centrifuged at 3,500 x g for 20 min in a refrigerated centrifuge. The pellet (about 1.0 ml) was transferred to a conical tube with volume marks. The Falcon tubes were washed with 1.0 ml of 0.2% bovine albumin solution, and this mixture was also added to the conical tube. The volume of this concentrated specimen was adjusted to 2.5 ml with the bovine albumin solution. Two 7H11 agar plates were inoculated with this specimen without any dilution (0.5 ml each), and an additional plate was inoculated with 0.5 ml of the specimen diluted to 1:100. The inoculum was spread by tilting the plates. In addition, 1.0 ml of the concentrated specimen was inoculated in a BACTEC 7H12 broth vial for rapid recovery of growth. The colonies were counted after incubation of the plates for 3 weeks at 37°C in the presence of 5% CO2, and the number of CFU per milliliter of blood was calculated.
Drug susceptibility tests. The MICs of clarithromycin for the M. avium clinical isolates and the drug-resistant mutants were determined radiometrically in 7H12 broth at pH 7. 256.0->512.0 >512.0 azithromycin described in our previous report (12) . The MICs of the other drugs were also determined radiometrically in 7H12 broth according to the detailed description given in our review of this method (11) . In addition, 7H11 agar plates were used for a direct susceptibility test to inoculate blood from patients treated with clarithromycin. These plates had one drug-free quadrant and three quadrants containing clarithromycin incorporated at concentrations of 16.0, 32.0, and 64.0 ,ug/ml, respectively. We did not receive any blood specimens from patients treated with azithromycin, and therefore, the direct susceptibility test was limited to clarithromycin only. Our previous studies (12) have shown that the highest MIC of clarithromycin for M. avium strains from patients who were never treated with a macrolide was 4.0 ,ug/ml when tested on Mueller-Hinton agar. Taking into account the possibility of one twofold dilution error (MIC, 8.0 ,ug/ml for 1 of 50 strains tested in our previous study [12] ), we used a concentration range of 16.0 to 64.0 ,g/ml to detect drug-resistant bacteria in the direct test. The agar plates were inoculated with the blood specimens after they had been processed for isolation and quantitative cultures as described above. The number of colonies found in the clarithromycin-containing quadrants was compared with the counts in the drug-free quadrant to determine the proportion of resistant bacteria.
RESULTS
Drug-resistant mutants selected in vitro. For four M. avium strains isolated from patients who were never before treated Table 2) .
The colonies found on the drug-containing quadrants of the plates were transferred to agar slants containing the same concentrations of the drug. In 7H12 broth, the MICs of clarithromycin for all of these subcultures were 128.0 to 512.0 p,g/ml for all four strains, regardless of the concentrations (16.0 to 64.0 ,uglml) of drug in Mueller-Hinton agar in which the mutant colonies grew. The MICs of azithromycin for all the mutant colonies that grew in the presence of this drug were greater than 512.0 ,ug/ml; this concentration did not inhibit growth in 7H12 broth, but we were unable to perform the test at higher concentrations because the drug was insoluble at those concentrations.
Mutants that grew in the presence of either of the two macrolides were resistant to high concentrations of the other drug (Table 3) , indicating cross-resistance between clarithromycin and azithromycin.
The original four strains and the clarithromycin-and azithromycin-resistant mutants derived from them were tested with seven other drugs that are conventionally used in Among the eight patients, three had received clarithromycin at 500 mg b.i.d. and five had received clarithromycin at 1,000 mg b.i.d. The time required to achieve the lowest level of bacteremia depended on the intensity of the pretreatment bacteremia (Table 5) , and the difference was statistically significant (P < 0.05) between the groups with an initial level of bacteremia of less than 86 CFU/ml, 101 to 894 CFU/ml, and greater than 1,031 CFU/ml. The negative cultures or the lowest level of bacteremia were achieved sooner in the group of 20 patients that received 1,000 mg b.i.d.; it took an average of 38.3 days in this group and an average of 56.8 days in the group of 18 patients receiving clarithromycin at 500 mg b.i.d., and this difference was statistically significant (P < 0.05). All 38 responders had a relapse of bacteremia after an average of 123.8 days of therapy, regardless of the dosage of drug administered ( Table 6 ). The period of the low levels of bacteremia (negative cultures or a few CFU per milliliter) before the relapse depended on the initial intensity of bacteremia in a range of 101.3 to 42.7 days (Table 6 ), and this difference was statistically significant (P < 0.05).
Because it took longer to achieve low levels of bacteremia in the group that received clarithromycin at 500 mg b.i.d. rather than 1,000 mg b.i.d., the patients who received the higher dose had a relatively longer period of low bacteremia than those who received 500 mg (an average of 87.2 versus 65.1 days). The patterns of bacteremia are shown in Fig. 1 and 2.
Susceptibilities of strains isolated from patients treated with clarithromycin. All isolates obtained in culture before treatment and during the period of decline of bacteremia, a total of 162 isolates from 38 patients, were susceptible to clarithromycin at concentrations ranging from 0.12 to 2.0 ,ug/ ml. All isolates obtained in cultures at the very beginning of . for a period of greater than 150 days (more than eight visits). The curves of the number of viable bacteremia per milliliter of blood are distributed in four graphs according to the initial level of bacteremia: less than 100 CFU/ml (six patients) (a) 100 to 1,000 CFU/ml (four patients) (b), 1,000 to 10,000 CFU/ml (six patients) (c), and greater than 10,000 CFU/ml (two patients) (d).
the relapse of bacteremia and during the relapse, a total of 178 isolates, were resistant to these and substantially higher concentrations of clarithromycin: the MICs for these isolates were 256.0 ,ug/ml or greater (Table 7) . Isolates from six patients obtained in culture before therapy and during relapse were also tested with drugs other than clarithromycin. The results of those studies showed that the susceptibility patterns of the isolates for seven drugs (rifampin, ethambutol, ethionamide, streptomycin, ciprofloxacin, clofazimine, and cycloserine) other than the macrolides remained unchanged, but the isolates became resistant to azithromycin at a concentration of greater than 512.0 ,g/ml.
Results of direct susceptibility tests with blood specimens. To determine the proportion of clarithromycin-resistant and clarithromycin-susceptible bacteria in blood specimens obtained during the period of relapse of bacteremia, specimens were inoculated onto 7H11 agar plates divided into quadrants in which one quadrant was drug-free and the three other quadrants contained clarithromycin incorporated at concentrations from 16.0 to 64.0 ,ug/ml. The results of those studies with 12 specimens showed that the number of colonies that grew on drug-free and drug-containing quadrants did not differ substantially. The subcultures from colonies grown on the drug-containing quadrants were tested for the MICs of clarithromycin, which were all 256.0 ,ug/ml or greater, whereas not a single subculture was found to be susceptible to clarithromycin at 2.0 ,g/ml. DISCUSSION M. avium strains isolated from patients that have not been treated with macrolides are always susceptible to clarithromycin at concentrations of 2.0 ,ug/ml or less in 7H12 broth at pH 7.4 and 8.0 ,ug/ml or less in Mueller-Hinton agar at the same pH (12) . The strains tested in the present study were susceptible to azithromycin at 8.0 to 16.0 ,g/ml in broth and 32.0 to 64.0 ,g/ml in agar when tested under the same growth conditions. Cultivation of these isolates in the presence of higher concentrations of these two macrolides revealed a low proportion of resistant mutants with a frequency of 1.1 x 10-9 to 6.7 x 10-8 for clarithromycin and 1.1 x 10-10 to 1.2 x 10-6 for azithromycin. Determination of the frequency of occurrence of M. avium mutants resistant to macrolides was the first step in approaching this new phenomenon. However, the frequency of occurrence of mutants may be considered an approximate reflection of the mutation rates that later should be determined in appropriately designed studies.
The broth-determined (at pH 7.4) MICs of clarithromycin for either clarithromycin-or azithromycin-resistant mutants were 128.0 ,ug/ml or greater. The MICs of azithromycin for both types of mutants were greater than 512.0 p,g/ml. These data demonstrate that there is cross-resistance between these two macrolides. Clarithromycin-resistant strains isolated from patients during the relapse of bacteremia after a prolonged period of monotherapy with this drug were also 20 patients treated with 1,000 mg of clarithromycin twice daily for a period of greater than 150 days. Initial levels of bacteremia were less than 1,000 CFU/ml (five patients) (a), 100 to 1,000 CFU/ml (seven patients) (b), 1,000 to 10,000 CFU//ml (six patients) (c), and greater than 10,000 CFU/ml (two patients) (d).
resistant to azithromycin. For strains isolated from patients with bacteremia before treatment, MICs of clarithromycin ranged from 0.12 to 2.0 pg/ml and the MICs of azithromycin ranged from 8.0 to 16.0 ,ug/ml. The MICs for strains isolated from the same patients during the relapse of bacteremia after prolonged monotherapy with clarithromycin showed that the strains were resistant to both drugs; the MICs of clarithromycin were 256.0 p,g/ml or greater and the MICs of azithromycin were greater than 512.0 p,g/ml, thus confirming the cross-resistance between these two macrolides.
Comparison of strains that were susceptible and resistant to the macrolides in pairs, which was done by using either artificially selected resistant mutants or those isolated from patients before treatment 1, 024 .0 ,ug/ml). The levels of bacteremia increased in intensity (as CFU per milliliter), despite continuous therapy. These data indicate that the relapses were associated with the emergence of drug resistance as a result of multiplication of the preexisting clarithromycin-resistant mutants. These data also provide an opportunity to establish a criterion to define the "resistance" of strains to clarithromycin. All isolates obtained in culture during the relapse of bacteremia were resistant to 128 ,ug of clarithromycin per ml, and we did not find a single strain for which the broth-determined MIC was 8.0, 16.0, 32.0, or 64.0 ,ug/ml. Nevertheless, pragmatically, detection of a clarithromycin-resistant strain is more convenient in the clinical laboratory setting by using concentrations of less than 128.0 ,ug/ml, for example, 16 .0 FLg/ml in broth. We would suggest calling the strain "resistant" to clarithromycin if the MIC determined in 7H12 broth at pH 7.4 was greater than 16.0 ,ug/ml. An equivalent for a test in MuellerHinton agar would be 64.0 ,ug/ml.
The direct susceptibility test with blood specimens obtained during the relapse of bacteremia indicated the absence of any proportion of the bacterial population that was still susceptible to clarithromycin, which suggests that the relapse of bacteremia is not jufst associated with the emergence of drug resistance but is caused exclusively by the clarithromycin-resistant mutants. This observation is also an indication that the overwhelming part of the original bacterial population that was susceptible to 2.0 p,g of clarithromycin per ml or less was completely eliminated during the initial period of treatment that led to a dramatic decrease in the level of bacteremia.
The emergence of drug resistance in isolates from patients on monotherapy for mycobacterial infections is not a new phenomenon. In the early stages of antimicrobial therapy of tuberculosis, monotherapy with streptomycin or isoniazid led to an initial decrease in the number of tubercle bacilli found in sputum; this was followed by the emergence of drug resistance and an increase in the number of bacilli in sputum (8, 15, 25) . These events were described as the "fall and rise phenomenon" and led to the principle of multiple-drug therapy with the purpose, initially, to prevent the emergence of drug resistance. The events that took place in the patients with disseminated M. avium infections treated with clarithromycin for a prolonged period of time have a striking similarity to the fall and rise phenomenon described in the early years of monotherapy for tuberculosis. Therefore, the prevention of the emergence of drug resistance to clarithromycin is very likely to be achieved by the introduction of an appropriate drug combination.
